Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Trial of A-dmDT390-bisFv(UCHT1) Fusion Protein in Combination With Ionizing Radiation for the Treatment of Stage IV Melanoma

NCT01888081 is registered in ClinicalTrials.gov with Virogen Biotechnology Inc. as lead sponsor.

NCT NCT01888081
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01888081 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Trial of A-dmDT390-bisFv(UCHT1) Fusion Protein in Combination With Ionizing Radiation for the Treatment of Stage IV Melanoma
Lead sponsor
Virogen Biotechnology Inc.
Phase
Phase 1/2
Overall status
Terminated
Start date
February 28, 2014
Completion date
Not reported
Enrollment
2 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma